Kyverna Therapeutics Inc KYTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KYTX is a good fit for your portfolio.
News
-
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
-
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
-
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
-
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
-
Wall Street hungry for IPO of Mexican supermarket chain BBB Foods as stock rises 9%
Trading Information
- Previous Close Price
- $13.07
- Day Range
- $13.04–14.08
- 52-Week Range
- $11.75–35.06
- Bid/Ask
- $13.25 / $15.00
- Market Cap
- $592.40 Mil
- Volume/Avg
- 19 / 422,486
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 84
- Website
- https://www.kyvernatx.com
Valuation
|
Metric
|
KYTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.56 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KYTX
|
|---|---|
Quick Ratio | 2.90 |
Current Ratio | 3.05 |
Interest Coverage | −334.02 |
Quick Ratio
KYTX
Profitability
|
Metric
|
KYTX
|
|---|---|
Return on Assets (Normalized) | −38.67% |
Return on Equity (Normalized) | −183.09% |
Return on Invested Capital (Normalized) | −155.48% |
Return on Assets
KYTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Wcgpgbt | Xsrbv | $124.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vxdvgqcs | Gvjwxm | $111.3 Bil | |||
| Moderna Inc
MRNA
| Tzdfhgvyg | Wlzf | $56.9 Bil | |||
| BioNTech SE ADR
BNTX
| Tdbgytfwc | Zpx | $24.2 Bil | |||
| argenx SE ADR
ARGX
| Knswltyt | Ggwn | $22.5 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kwvgrgvm | Xskbvh | $20.1 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dlfgyzfrh | Phcsz | $16.1 Bil | |||
| Incyte Corp
INCY
| Szlqfsqqy | Jvxnzv | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Krcyxmvjh | Prmdrl | $12.4 Bil | |||
| United Therapeutics Corp
UTHR
| Vndtdtww | Ywj | $12.2 Bil |